Bronchiolitis obliterans syndrome (BOS) is a severe, progressive lung disorder characterized by inflammation and fibrosis of the small airways, leading to irreversible airflow obstruction. According to Guang-Shing Cheng et al., 2025, BOS and other late-onset noninfectious pulmonary complications (LONIPCs) affect as many as 20% of allogeneic hematopoietic cell transplant (HCT) recipients, contributing to significant morbidity and mortality for individuals who have been cured of hematologic disease. According to the bronchiolitis obliterans syndrome pipeline analysis by Expert Market Research, increasing prevalence and the urgent need for effective therapies are expected to drive significant growth in the coming years.
Major companies involved in the bronchiolitis obliterans syndrome pipeline analysis include Renovion, Inc., OrphAI Therapeutics, and others.
Leading drugs currently in the pipeline include ARINA-1, LAM-001, and others.
The pipeline is expanding with several novel immunomodulators and antifibrotic therapies. Increased clinical trials and strategic collaborations are expected to drive significant market growth.
The Bronchiolitis Obliterans Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bronchiolitis obliterans syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bronchiolitis obliterans syndrome. The bronchiolitis obliterans syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bronchiolitis obliterans syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bronchiolitis obliterans syndrome guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bronchiolitis obliterans syndrome.
Read more about this report - Request a Free Sample
Bronchiolitis obliterans syndrome (BOS) is a progressive, non-reversible lung disease characterized by inflammation and fibrosis of the small airways, often occurring after allogeneic hematopoietic cell transplantation or lung transplantation. It develops due to immune-mediated injury, chronic graft-versus-host disease, infections, or toxic insults, leading to airflow obstruction, reduced lung function, and respiratory decline.
Bronchiolitis obliterans syndrome treatments include immunosuppressive therapy, corticosteroids, anti-fibrotic agents, and targeted biologics to manage inflammation, slow fibrosis, and improve lung function in affected patients. An example from the Bronchiolitis Obliterans Syndrome market drug pipeline is ruxolitinib. In February 2025, a study demonstrated significant improvement in lung function, particularly in patients diagnosed within six months. The drug achieved a median National Institutes of Health response time of 7.7 months and represents a promising approach for managing fibrosis and inflammation in BOS patients.
The bronchiolitis obliterans syndrome (BOS) drug pipeline is rapidly evolving to tackle the growing clinical challenges and unmet patient needs. Guang-Shing Cheng et al., 2025, report that BOS and other late-onset noninfectious pulmonary complications affect up to 20% of allogeneic hematopoietic cell transplant recipients. Jacqueline S. Dickey et al., 2024, note that chronic graft-versus-host disease impacts 50% of these patients, with lung involvement manifesting as BOS in 5-14% of cases. Pipeline advancements aim to address these unmet medical needs.
This section of the report covers the analysis of bronchiolitis obliterans syndrome drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The bronchiolitis obliterans syndrome pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 52%, holds the largest share of the total bronchiolitis obliterans syndrome clinical trials. It is followed by phase I at 25%, reflecting strong mid-stage development. Phase III, at 11.76%, indicates ongoing late-stage progress. This distribution underscores a robust and advancing pipeline, with the progression of these therapies through clinical phases expected to expand treatment options, improve patient outcomes, and drive market growth.
The drug molecule categories covered under the bronchiolitis obliterans syndrome pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides and polymers. The bronchiolitis obliterans syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bronchiolitis obliterans syndrome. In the bronchiolitis obliterans syndrome drug pipeline, immunosuppressive therapies are advancing as potential treatments. For example, Liposomal Cyclosporine A for Inhalation (L-CsA-i) is under Phase III evaluation in the BOSTON-3 extension trial. Administered via the eFlow® Technology nebulizer, it targets T-cell-mediated airway inflammation post single or double lung transplant, aiming to improve long-term outcomes and reduce disease progression.
The EMR report for the bronchiolitis obliterans syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bronchiolitis obliterans syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bronchiolitis obliterans syndrome clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bronchiolitis obliterans syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bronchiolitis obliterans syndrome drug candidates.
ARINA-1 is a novel nebulized immunomodulatory agent sponsored by Renovion, Inc. This Phase 3 study is evaluating ARINA-1 in preventing the progression of bronchiolitis obliterans syndrome (BOS) in participants with bilateral lung transplants. The study is examining ARINA-1’s ability to improve quality of life, reduce airway inflammation, and delay the need for augmented immunosuppression compared to Standard of Care. ARINA-1 is actively restoring lung function by clearing mucus and modulating immune responses.
LAM-001 is a proprietary dry powder inhaled formulation of sirolimus. It is under evaluation in lung transplant recipients with bronchiolitis obliterans syndrome (BOS) under the INSPO-BOS study. Sponsored by Steven Hays, MD, at the University of California, San Francisco, this Phase 2 trial is examining the safety, tolerability, and efficacy of LAM-001 in slowing BOS progression. Participants are inhaling LAM-001 or placebo daily for 48 weeks, while undergoing pulmonary testing, bronchoscopy, lab evaluations, and home spirometry monitoring. The study is also assessing mTOR pathway inhibition and sirolimus lung deposition, aiming to reduce systemic toxicity compared to oral therapy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bronchiolitis Obliterans Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bronchiolitis obliterans syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bronchiolitis obliterans syndrome collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share